Business Paid
Synektik to spin off Syn2bio
02:45
Synektik, a provider of medical solutions and radiopharmaceuticals, plans to split into two independent companies. The listed firm will transfer its cardiomarker research and related R&D activities to a new entity, Syn2bio, with both companies remaining on the Warsaw Stock Exchange.
The spin-off aims to secure additional funding for clinical trials and…
This article is for subscribers
Warsaw Business Journal subscribers get the full archive (12,248 articles going back to 1995) and the print edition.
SubscribeOr try Poland A.M. free for 7 days, the daily briefing, or see all plans and prices.
